PT-141 vs Testosterone for Low Libido in Men: Which One Actually Works?

Thirty to forty percent of men on testosterone replacement therapy still report low libido after their testosterone normalizes. Their T comes up. Erections often improve. But the desire to initiate sex does not return the way they expected. This is not a dosing failure. It is a category error: testosterone fixes one problem, and low libido is often a different problem entirely.

PT-141 (bremelanotide) was designed for exactly this scenario. It does not touch your hormones. It fires a brain signal via the melanocortin system that triggers desire directly, regardless of what your blood test says. The question is not which compound is better. The question is which problem you actually have.

That refill number is the closest thing to a real-world satisfaction signal available for bremelanotide in men. No large Phase 3 RCT specifically in men has been completed. What exists is four decades of male TRT data on one side, and a growing body of off-label clinical experience on the other. This article puts both sets of evidence next to each other so you can make an informed choice.

What TRT actually does for libido (the numbers are smaller than you think)

The largest independent pooling of testosterone trial evidence available is a Cochrane-abridged systematic review published in the World Journal of Men's Health in 2025, covering 43 randomized controlled trials and over 11,000 men. The headline finding on libido is not what most TRT advocates lead with: the mean difference in erectile function scores (IIEF-EF) between TRT and placebo was 2.37 points. Effects on sexual quality of life were described as "little to no difference."

That is not the same as saying TRT does not work. It means TRT does not work uniformly across all men with low libido. A separate 2024 meta-analysis in Frontiers in Endocrinology (28 RCTs, n=3,461) found a statistically significant IIEF improvement of 3.26 points in men with confirmed hypogonadism. The gap between these two reviews points to the same thing: TRT works best in men who are genuinely deficient, and its effect on desire specifically shrinks as testosterone approaches the normal range.

When TRT works well for libido

The 2024 International Consultation on Sexual Medicine guidelines (published as Rastrelli et al., Sexual Medicine Reviews, 2025) give a strong recommendation to measure and treat testosterone in men with reduced sexual desire, using a threshold around 8-15 nmol/L (230-430 ng/dL) depending on clinical context. Eight prior meta-analyses spanning 2005-2022 all found testosterone significantly improves sexual desire in this range, with positive effect sizes across all studies. If your testosterone is below 300 ng/dL with symptoms, TRT is the first-line option with the strongest evidence base.

The TRAVERSE trial, published in the New England Journal of Medicine in 2023, provided the most reassuring long-term safety data the field has ever produced: in over 5,000 hypogonadal men followed for two years, TRT outperformed placebo on sexual activity and libido while showing no increase in major cardiovascular events. The FDA removed the cardiovascular black-box warning from TRT labels in early 2025 based on this data.

When TRT falls flat

The Cochrane-abridged review surfaces what every experienced endocrinologist already knows: testosterone does not reliably restore desire in men whose T is already in the normal or low-normal range. When testosterone is above 400 ng/dL, the evidence for desire improvement essentially disappears. If you are in that range and still have low libido, you are likely facing a central signaling problem, not a hormonal deficit. TRT will not solve it.

The distinction between desire disorder and testosterone deficiency matters enormously for treatment selection. Correcting testosterone in a man whose levels are already adequate does not restore sexual desire, because desire is regulated at the central nervous system level through pathways that testosterone influences only partially.

Rastrelli et al., Sexual Medicine Reviews, 2025 (ICSM 2024 Guidelines)

What PT-141 does that testosterone cannot

Bremelanotide binds the melanocortin-4 receptor (MC4R) in the hypothalamus and activates dopaminergic neurons in the mesolimbic reward pathway. This is not a peripheral mechanism. It is not a vascular mechanism. It fires the brain's desire signal directly. The result is spontaneous sexual motivation appearing 45-60 minutes after a subcutaneous injection, independent of testosterone level.

This is also the mechanism PDE5 inhibitors (Viagra, Cialis) do not touch. Those drugs improve blood flow to the penis when arousal is already present. They require desire as a prerequisite. PT-141 creates the desire that then makes PDE5 inhibitors fully effective, which is why the most promising clinical data involves combining both. The full PT-141 mechanism guide covers the dopamine pathway in more detail if you want the mechanistic background.

The evidence specifically in men

No large Phase 3 RCT of bremelanotide in men has been completed. The foundational controlled data in men comes from an earlier Phase 2 study by Molinoff et al. published in the International Journal of Impotence Research: in men who were partial non-responders to sildenafil, bremelanotide produced erections sufficient for intercourse in 34% of subjects versus 9% on placebo. This is a practically important endpoint: men who did not fully respond to Viagra, responding to the central pathway PT-141 targets.

Palatin Technologies, which holds the bremelanotide patent for male indications, initiated a Phase 2 open-label trial on June 20, 2024 testing bremelanotide co-administered with a PDE5 inhibitor in approximately 50 men with ED who did not respond to PDE5i monotherapy. Topline results were originally expected by end of 2024 and now are targeted for H1 2026. A referenced earlier RCT found the combination increased the duration of erectile activity by an average factor of 5.3. The Phase 2 results have not yet been published in peer-reviewed form as of this article.

In the meantime, the Goldstein and Goldstein studies at San Diego Sexual Medicine represent the largest real-world dataset. The December 2024 Journal of Sexual Medicine abstract analyzed 444 male bremelanotide dispensations across 46 months. Men showed 52% improvement in erectile dysfunction, 39% improvement in hypoactive sexual desire specifically, and 39% improvement in sexual performance anxiety. The 65% refill rate was higher than any female subgroup. The limitation is obvious: it is one clinic, no control group, and refill rate is a satisfaction proxy not a clinical endpoint. But for off-label use with no Phase 3 data, this is the most informative real-world signal available.

What the 2024 clinical guidelines actually say about PT-141 for men

Here is the finding that gets buried in most PT-141 content. The ICSM 2024 guidelines, the most authoritative clinical consensus on sexual medicine, include a conditional recommendation that "available studies do not support using analogs of alpha-MSH for improving sexual desire and erectile function in men, due to associated adverse events." The evidence quality was graded as low.

This does not mean PT-141 does not work in individual cases. It means the guideline committee, reviewing the same evidence base you have access to, concluded the formal RCT evidence for men is not yet strong enough to recommend it as a standard clinical treatment. The adverse events driving the caution are nausea (roughly 30-40% of users), transient blood pressure increases, and facial flushing. These are real and common, but most practitioners report they diminish by starting at a lower dose (0.5-1 mg rather than 1.75 mg).

The well-calibrated read on PT-141 for men in 2026: promising real-world data, a biologically compelling mechanism, a conditional guideline caution, and the pivotal Phase 2/3 combination trial results still pending. It is not unproven snake oil. It is also not at the level of evidence TRT carries after 40 years of RCTs. You can read more about how your metabolic genes change peptide clearance and dosing in the CYP3A4 slow metabolizer guide.

PT-141 vs testosterone: direct comparison

Factor	Testosterone (TRT)	PT-141 (Bremelanotide)
Target	Hormonal deficit (low T)	Central desire signal (brain)
FDA approval for men	Yes (hypogonadism)	No (approved for women only as Vyleesi)
Onset of action	Weeks to months	45-60 minutes
Dosing style	Daily, weekly, or biweekly	On-demand, max 1x per 24 hours
Strongest trial	TRAVERSE (NEJM, 2023): 5,000+ men, 2 years	Goldstein real-world data (JSM, Dec 2024): 444 dispensations; no Phase 3 RCT in men
Effect on desire specifically	Modest (IIEF mean difference 2.37 in Cochrane review)	39% HSDD improvement in off-label clinic data
Main side effects	Erythrocytosis, testicular atrophy, acne, fertility suppression	Nausea (30-40%), transient blood pressure increase, flushing
Best candidate	T below 300 ng/dL with symptoms	Normal T with absent desire; TRT partial-responders on libido
Current guideline stance	Strong recommendation (ICSM 2024)	Conditional recommendation against alpha-MSH class (ICSM 2024)
DEA scheduling	Schedule III controlled substance	Not a controlled substance; requires prescription
Can be combined	Yes, additive with PT-141	Yes, additive with TRT and PDE5 inhibitors

Which one do you actually need?

Start with your testosterone number. If it is below 300 ng/dL (10.4 nmol/L) with symptoms, TRT is your first move. The evidence is robust, the safety profile after TRAVERSE is well-established, and restoring T to mid-normal range resolves most of what many men are missing. Get the bloodwork before anything else.

If your testosterone is already normal and desire is still absent, the hormonal path is a dead end. Your problem is central, not peripheral. PT-141 targets this pathway directly and the mechanism is well-established even if the Phase 3 evidence in men is still building. The full PT-141 guide covers dosing, nausea management, and the compounding status in detail. Starting at 0.5 mg to test your nausea threshold before moving to 1.75 mg is the standard approach used in clinical settings.

If you are already on TRT and your T is normalized but libido remains low, combining both makes biological sense. TRT handles the androgen component. PT-141 handles the central desire component. They do not interact pharmacologically and the combination has not been tested in a formal RCT, but the clinical logic is sound and the Palatin Phase 2/3 combination trial should provide clarity by H1 2026.

The genetics angle matters. Your MC4R receptor density affects how strongly PT-141 fires the desire signal. Your androgen receptor CAG repeat length affects how sensitive your tissues are to testosterone. A DNA-first decision framework can show you which pathway is most likely to produce a measurable result before you spend months trying both.